Long-Term Benefits of Tivozanib: Insights From the TIVO-3 Study

Katy Beckermann, MD, PhD, of Vanderbilt-Ingram Cancer Center, and Thomas Hutson, DO, PharmD, FACP, of Baylor University Medical Center, summarize the TIVO-3 study for patients with relapsed or refractory advanced RCC, the recently reported long-term follow-up data, and what subgroup analyses tell us about the benefit of this treatment approach when factoring age and prior immunotherapy exposure.